Credevo

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Credevo, Health/Medical/ Pharmaceuticals, Singapore.

A global Clinical Trial Organization (CTO) providing comprehensive clinical trial services for pharmaceuticals, biologics, medical devices and healthcare products Credevo provides strategic support for healthcare products including;

- Drugs

- Biologics

- Health Supplements (Nutraceuticals)

- IVD and medical devices

- Cosmetics

In areas of

- Regulatory

- Clinical Development

- Business Development Support

- Licensing (out-/in-)

- Feasibility

10/03/2026

Oncology trials are some of the hardest studies to run.

Recruitment can be slow. Protocols are often complex. Data volumes are large. Add multiple countries and regulators, and timelines can start slipping if the operational plan is not practical from the start.

In many cases, delays do not come from one big issue. They build up from several smaller operational gaps that show up during the study.

A few areas tend to make a clear difference:

• Trial design built around real patient availability and site feasibility
• Simpler protocols with site feedback early in the process
• Risk-based monitoring to focus attention where it matters most
• Early planning for regulatory requirements across regions
• Strong coordination with FSP teams and key vendors

When these elements are in place, teams spend less time solving day-to-day operational issues and more time keeping the study on track. Data collection also becomes more consistent across sites.

If you are planning an oncology study or dealing with operational challenges in one, it may help to review the study setup and site strategy.

If you’d like to talk it through, you can reach us here:
credevo.com/contact

10/03/2026

🌍 Global Clinical Trials in Orphan Drug Development

Rare disease research runs into a simple limitation. Patient numbers are small and spread across countries. Many conditions also show genetic differences between populations. A trial limited to one country often struggles to enroll enough participants or produce data regulators consider sufficient.

Global trials address that gap.

🔬 What global trials make possible
• Access to a broader pool of rare disease patients
• Data that reflects genetic and geographic diversity
• Evidence that can support submissions to agencies such as the FDA, EMA, PMDA, MFDS, and TGA
• A clearer path to approvals in multiple regions

⚠️ Where studies often slow down

Several operational issues appear repeatedly in orphan drug trials:
• Recruitment that takes longer than planned
• Regulatory differences between countries
• Variations in data collection or protocol adherence across sites

💡 Approaches that tend to work

• Select countries and sites based on verified rare-disease feasibility data
• Keep endpoints and protocols consistent across regions
• Plan the regulatory path early, including pediatric requirements, designations, and label goals

Credevo works with sponsors on global orphan drug trials, from feasibility and site identification to regulatory planning and study ex*****on.

📩 Working on an orphan drug program or planning a rare disease trial?
👉 https://credevo.com/contact

🌍

09/03/2026

🌏 Traditional Medicine Clinical Trials Often Work Best in Asia-Pacific

Developers of herbal and traditional medicines face a familiar problem. They need clinical evidence that regulators accept, while keeping the diagnostic methods and treatment principles used in traditional practice.

Asia-Pacific offers conditions that make this easier.

🔬 What the region offers
• Long-established medical systems such as Ayurveda, Traditional Chinese Medicine (TCM), Kampo, and Korean Medicine
• Access to a large and diverse patient population (around 60% of the world’s population lives in this region)
• High patient familiarity with traditional therapies, which can support recruitment and retention
• Trial costs that are generally lower than in many Western regions
• Regulatory systems aligned with GCP and a growing network of experienced research sites

⚠️ Where trials often run into difficulty
Traditional medicine studies can face issues such as variation in formulations, practitioner-driven diagnostic methods, and different regulatory expectations across countries. These factors can slow study start-up or complicate data consistency.

💡 What helps studies move forward
Careful country selection, experienced sites, clear protocols, and consistent quality controls make a measurable difference in these trials.

Credevo supports traditional medicine clinical studies across Asia-Pacific.

📘 Read the full article
🔗 https://tinyurl.com/3ytv7uxk

📩 Planning a traditional medicine trial?
Connect with us 👉 https://credevo.com/contact

🌿

06/03/2026

🏥 Site selection often determines how a clinical trial unfolds.

A site with the right patient population, infrastructure, and study team can keep enrollment steady and timelines predictable. When those factors are misjudged, delays tend to appear later in recruitment or startup.

📄 One of the simplest ways to understand site readiness early is a well-structured Site Feasibility Questionnaire.

Used properly, the questionnaire opens a practical discussion with investigators and study teams before the trial begins. It helps sponsors understand where patients are treated, how sites manage similar studies, and what operational constraints may affect recruitment.

Clear feasibility questions can help teams:

• Identify sites that regularly treat patients within the study indication
• Understand investigator experience and available infrastructure
• Review regulatory and operational readiness at each site
• Surface potential recruitment challenges early
• Align site expectations with the study protocol

This information helps sponsors make more confident site selection decisions and plan recruitment with fewer surprises later in the trial.

Credevo works with sponsors and CRO teams on feasibility planning and site selection for global clinical trials.

📚 If you would like to review an example feasibility questionnaire, we have shared a resource here:
https://tinyurl.com/2st3t5st

You can also reach us here if you want to discuss site feasibility planning for an upcoming study:
credevo.com/contact

05/03/2026

⏳ Trial timelines often slip during the earliest phases of study startup.

🌍 Site selection, investigator alignment, and recruitment planning shape how smoothly a study moves once enrollment begins. When these steps happen late or without site input, delays usually follow.

Sponsors that involve investigators and sites early tend to see clearer recruitment forecasts, fewer protocol adjustments, and faster study startup.

A few practical outcomes of early engagement:

• Recruitment challenges identified before enrollment begins
• Protocols reviewed against real clinical practice, which can reduce amendments
• Faster site activation and earlier enrollment ramp-up
• Earlier alignment between sponsors, investigators, and study teams
• Site relationships that carry into future programs

In clinical development, early operational clarity often determines how predictable a trial will be.

Credevo works with sponsors during study planning and startup to help teams engage investigators early and build practical recruitment strategies.

If you're planning a new trial or reviewing startup timelines, feel free to reach out.

🔗 credevo.com/contact

04/03/2026

Complex trials demand proactive thinking, not reactive fixes.

Our early engagement approach helps de-risk recruitment, refine design, and strengthen ex*****on from day one.

Let’s engage early and accelerate your path forward.
www.credevo.com
inquiry@credevo.com

03/03/2026

Is your nutraceutical supported by strong clinical evidence?

With increasing regulatory scrutiny on health claims, many nutraceutical brands face delayed approvals, limited credibility, and barriers to global expansion due to insufficient human data.

India is emerging as a strategic solution.

With over 1.4 billion people and significant genetic diversity, India offers a robust participant pool for clinically meaningful outcomes. From 2019 to 2024, 111 nutraceutical clinical studies were registered, reflecting growing research momentum.

Why conduct nutraceutical trials in India?
🔬 Structured regulatory pathway
Approvals from Institutional Ethics Committees and the Central Drugs Standard Control Organization ensure compliance. Nutraceutical categories are defined by the Food Safety and Standards Authority of India, creating regulatory clarity.
💰 Cost efficiency
Clinical trials can be 30 to 60 percent more economical than in Western markets, while aligning with ICH-GCP standards.
🌍 Diverse population insights
Variations in genes and microbiome profiles influence responses to curcumin, omega-3 fatty acids, and probiotics. India’s diversity enables globally relevant, population-specific data.
🏥 Strong research ecosystem
GCP-compliant sites and institutions such as the Indian Council of Medical Research support high-quality ex*****on.

The global nutraceutical market surpassed USD 450 billion and continues to grow rapidly, driven by preventive healthcare demand.

At Credevo, we help sponsors navigate regulations, design compliant studies, and generate globally acceptable clinical evidence.

Planning your nutraceutical clinical trial in India?
Connect with our experts:
👉 https://credevo.com/contact

🔬🌍

02/03/2026

The next generic drug opportunity wave is already here, and the window to act is narrowing fast. ⏳

The pharmaceutical industry is approaching a patent cliff between 2026 and 2030, with approximately $180 to $200 billion in annual pharmaceutical revenue at risk from blockbuster drugs losing exclusivity. 🚨

For generic developers, this is one of the most significant opportunity windows of the decade. But here is where most programs stumble: delayed or poorly structured Bioequivalence (BE) planning.

Late BE study initiation means missed first-to-file advantages, compressed regulatory timelines, and costly development rework that erodes your competitive position before a single tablet reaches the market.

This is exactly the problem Credevo's BE Protocol Catalogue is built to solve. 🔬

Our ready-to-use BE study protocols for high-value reference listed drugs approaching loss of exclusivity between 2026 and 2030 are:
✅ Aligned with current FDA and EMA regulatory expectations
✅ Built on standard BE scientific frameworks covering PK endpoints, sampling strategy, and analytical considerations
✅ Complete with study design, rationale, statistical methodology, and safety framework
✅ Ready for immediate operational planning

The sponsors who plan BE studies earlier will reduce development risk and stay ahead in an increasingly competitive generic landscape. 📈

Got an upcoming generic program or looking to map out your BE strategy? Let's figure it out together.
👉 Browse our bioequivalence study protocol catalogue and identify upcoming generic opportunities:
https://credevo.com/s/bioequivalence-study-protocol-catalogue/

👉 Looking to discuss a specific product or strategy?
📩 Drop us a message here: https://credevo.com/contact

27/02/2026

🚨 Your generic drug is scientifically sound. But is it regulatory-ready for every market you want to enter?

A BA/BE study that clears FDA review can still face rejection when submitted to EMA, PMDA, ANVISA, or CDSCO. The science may be identical. The regulatory expectations are not.
And the stakes are real. The global generics market is projected to nearly double to USD $950 billion by 2034. Yet study failures remain common, often because only 45% of sponsors perform joint power calculations for both Cmax and AUC endpoints, leaving studies underpowered before a single subject is dosed.

📊 Every major agency applies its own layer of requirements:
FDA tightens NTI drug criteria with replicated crossover designs. EMA narrows the AUC acceptance window to 90.00 to 111.11% for NTI drugs. PMDA, Health Canada, and emerging market regulators add population-specific and documentation-specific demands on top.

A weak protocol signals a weak study, even before data is generated.
💡 That is exactly the problem we solve at Credevo.

Our ready-to-use BA/BE study protocols are built for multi-regional submissions across FDA, EMA, PMDA, CDSCO, ANVISA, and more, helping you reduce deficiency letters, avoid costly redesigns, and accelerate time-to-approval.
📄 Browse our protocol catalogue: https://credevo.com/s/bioequivalence-study-protocol-catalogue/

👉 Connect with our team: https://credevo.com/contact

26/02/2026

Clinical trial budget pressure often begins during protocol planning. 💡

As protocols become more complex, ex*****on becomes heavier for sites and costs rise quickly. Small inefficiencies at the design stage can translate into significant financial impact once a study is underway.

High screen failure rates, slow enrollment, operational delays, and protocol amendments are often linked to early design decisions. 📉
Eligibility criteria may limit real-world recruitment. Visit schedules may not reflect site capacity.

Once a protocol is finalized, changes become expensive across all participating sites. 💰
Involving investigators during protocol preparation helps validate recruitment assumptions and operational realities before budgets and timelines are locked. 🤝

At Credevo, we support sponsors with feasibility, investigator input, and protocol optimization at this stage to improve cost predictability and study readiness.

📩 Planning a new study? Let’s strengthen your protocol before costs escalate.
👉 https://credevo.com/contact

25/02/2026

🚨 Over 85% of clinical trials face delays, and a single day lost in drug development can cost sponsors more than $600,000.

For global sponsors running trials in Japan, customs and logistics bottlenecks are among the biggest, and most underestimated, contributors.

🇯🇵 Japan's PMDA operates within one of the world's most rigorous regulatory frameworks. A single documentation error or customs misclassification can hold shipments for up to 14 days, and 68% of life science organizations have experienced exactly this. For temperature-sensitive IMPs, these delays do not just cost money; they risk data integrity and patient safety.

The two most common reasons shipments are stopped? Incomplete documentation and the absence of a recognized, in-country Importer of Record (IOR).

This is why IOR and EOR services are not a logistics add-on. They are a regulatory necessity.
✅ The right IOR and EOR partner in Japan delivers:
🔹 Full PMDA and PMD Act compliance
🔹 Accurate documentation, translation and customs liaison
🔹 Cold chain management with real-time visibility
🔹 Up to 20% reduction in overall supply costs
🔹 Trial timelines accelerated by 1 to 2 weeks on average

At Credevo, our PMDA-aligned IOR and EOR services ensure your IMPs and trial materials move compliantly and on time, every time. Japan is complex. Your supply chain does not have to be.

📩 Let us take it from here 👉 https://credevo.com/contact

24/02/2026

Most generic drug programs don't fail because of a bad molecule. They fail because of where and how BA/BE studies are run.

Delayed ethics approvals. Bioanalytical gaps. Sites that don't survive FDA inspection. In 2025, the regulatory bar has risen across every major market, and a single deficiency response can cost you 12 to 18 months of lead time.

The global generic drugs market is projected to reach USD 817 billion by 2034 (Towards Healthcare, 2025). The window to capture that opportunity is narrow. Your BA/BE program cannot be the bottleneck.

India has become the global answer to this challenge. It supplies 20% of global generic drug exports by volume (IBEF), hosts the highest number of US FDA-approved plants outside the US, and delivers BA/BE data formally accepted by the FDA, EMA, Health Canada, TGA, ANVISA, and all ASEAN regulators.

One well-designed study from an Indian site can support simultaneous filings across multiple stringent markets. That is strategy, not just cost savings.

Got a BA/BE program in the works? Our team would love to help you think it through. 👉 https://credevo.com/contact

Address

Singapore

Website

https://credevo.com/

Alerts

Be the first to know and let us send you an email when Credevo posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Featured

The Prenatal Consultants
101 Irrawaddy Road, #15-05/06 Royal Square Medical Centre

Want your practice to be the top-listed Clinic in Singapore?

Credevo

10/03/2026

10/03/2026

09/03/2026

06/03/2026

05/03/2026

04/03/2026

03/03/2026

02/03/2026

27/02/2026

26/02/2026

25/02/2026

24/02/2026

Address

Website

Alerts

Shortcuts

Featured

Share

Category